BioSpace News Archive

Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the full year of 2023 and provided an update on progress toward achieving key corporate objectives.

SHINE Technologies will showcase its innovative capabilities for producing non-carrier-added lutetium-177 (n.c.a Lu-177), a radioisotope used in targeted cancer treatments, at the 7th Theranostic World Congress (TWC), March 22-24 in Santiago, Chile.

Aligos Therapeutics, Inc. today announced the initiation of the Phase 2a HERALD study of ALG-055009 in subjects with metabolic dysfunction-associated steatohepatitis (MASH). Screening of subjects has begun at clinical study sites across the U.S.

Arch Biopartners Inc. announced today that it has published a peer reviewed paper in the British Medical Journal Open (BMJ Open) detailing the results of the international Phase II human trial for LSALT peptide targeting acute lung and kidney inflammation in hospitalized patients infected with SARS-CoV-2 virus.

Biora Therapeutics, Inc today announced it will report financial results and provide a corporate update for the fourth quarter and full year ended December 31, 2023.

Cybin Inc today announced participation in the upcoming Public Ventures Discovery Day on March 19, 2024 in Dallas, TX.

ZyVersa Therapeutics, Inc. announces Institutional Review Board (IRB) approval of the Phase 2a clinical trial protocol to evaluate the efficacy and safety of Cholesterol Efflux Mediator VAR 200 in patients with diabetic kidney disease.